Inventor · disambiguated record
Hans-Wilhelm Schwaeble
Also filed as: SCHWAEBLE HANS-WILHELM
19 granted patents·56 pending applications·231 citations·filing 2005–2024
94Inventor score
Top patents by PatentIndex Score
75 records- 0196US9644035B2Methods for treating conditions associated with MASP-2 dependent complement activationOMEROS CORP·Filed 2013·Granted May 9, 2017·18 cites·15 claims
- 0296US8652477B2Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activationSCHWAEBLE HANS-WILHELM·Filed 2010·Granted Feb 18, 2014·61 cites·18 claims
- 0396US7919094B2Methods for treating conditions associated with MASP-2 dependent complement activationOMEROS CORP·Filed 2006·Granted Apr 5, 2011·86 cites·21 claims
- 0495US8840893B2Methods for treating conditions associated with MASP-2 dependent complement activationSCHWAEBLE HANS-WILHELM·Filed 2011·Granted Sep 23, 2014·36 cites·12 claims
- 0594US8951522B2Methods for treating conditions associated with MASP-2 dependent complement activationDEMOPULOS GREGORY A·Filed 2012·Granted Feb 10, 2015·19 cites·14 claims
- 0688US10870708B2Methods for inhibiting angiogenesis in a subject in need thereofOMEROS CORP·Filed 2017·Granted Dec 22, 2020·3 cites·3 claims
- 0788US2025059299A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2024·Application pending·0 cites
- 0887US10059776B2Methods for treating conditions associated with MASP-2 dependent complement activationOMEROS CORP·Filed 2017·Granted Aug 28, 2018·2 cites·14 claims
- 0986US2024228665A1Methods for treating conditions associated with masp-2 dependent complement activationOMEROS CORP·Filed 2023·Application pending·0 cites
- 1086US2024254257A1Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and DisordersOMEROS CORP·Filed 2023·Application pending·0 cites
- 1185US11981749B2Methods for treating conditions associated with MASP-2 dependent complement activationOMEROS CORP·Filed 2020·Granted May 14, 2024·1 cites·8 claims
- 1285US11525011B2Methods of inhibiting MASP-2-dependent complement activation in a subject suffering from catastrophic antiphospholipid syndromeOMEROS CORP·Filed 2019·Granted Dec 13, 2022·1 cites·12 claims
- 1385US2024076409A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2023·Application pending·0 cites
- 1481US11884742B2Methods for treating conditions associated with MASP-2 dependent complement activationOMEROS CORP·Filed 2019·Granted Jan 30, 2024·0 cites·14 claims
- 1581US2024352152A1Methods for inhibiting angiogenesis in a subject in need thereofOMEROS CORP·Filed 2024·Application pending·0 cites
- 1680US2024293465A1Methods for Treating and/or Preventing Graft-Versus-Host Disease and/or Diffuse Alveolar Hemorrhage and/or Veno-Occlusive Disease Associated with Hematopoietic Stem Cell TransplantOMEROS CORP·Filed 2023·Application pending·0 cites
- 1779US2025092157A1Methods for inhibiting fibrosis in a subject in need thereofUNIV LEICESTER·Filed 2024·Application pending·0 cites
- 1878US2024343830A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2024·Application pending·0 cites
- 1978US2022259325A1Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and DisordersOMEROS CORP·Filed 2021·Application pending·0 cites
- 2077US10736960B2Methods for inhibiting fibrosis in a subject in need thereofUNIV LEICESTER·Filed 2017·Granted Aug 11, 2020·3 cites·8 claims
- 2177US2022089781A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2021·Application pending·0 cites
- 2276US2022002439A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2021·Application pending·0 cites
- 2376US2024424091A1Methods for Inhibiting Fibrosis in a Subject in Need ThereofUNIV LEICESTER·Filed 2024·Application pending·0 cites
- 2476US2024124611A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2022·Application pending·0 cites
- 2575US11896621B2Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplantOMEROS CORP·Filed 2021·Granted Feb 13, 2024·0 cites·10 claims
- 2673US2024076408A1Methods for treating conditions associated with masp-2 dependent complement activationOMEROS CORP·Filed 2023·Application pending·0 cites
- 2773US2015166676A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2014·Application pending·0 cites
- 2872US11981748B2Methods for inhibiting angiogenesis in a subject in need thereofOMEROS CORP·Filed 2020·Granted May 14, 2024·0 cites·2 claims
- 2971US2022242972A1Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Paroxysmal Nocturnal HemoglobinuriaOMEROS CORP·Filed 2021·Application pending·0 cites
- 3071US2021054098A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2020·Application pending·0 cites
- 3170US2020048366A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2019·Application pending·0 cites
- 3270US2020190215A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationUNIV LEICESTER·Filed 2019·Application pending·0 cites
- 3368US11013772B2Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplantOMEROS CORP·Filed 2018·Granted May 25, 2021·0 cites·13 claims
- 3468US2020040104A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2019·Application pending·0 cites
- 3568US2019016824A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2018·Application pending·0 cites
- 3668US2009259019A1Masp-2, a complement fixing enzyme, and uses for itOMEROS CORP·Filed 2007·Application pending·0 cites
- 3767US12005117B2Methods for inhibiting fibrosis in a subject in need thereofUNIV LEICESTER·Filed 2020·Granted Jun 11, 2024·0 cites·13 claims
- 3867US2017166659A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2016·Application pending·0 cites
- 3967US2010074899A1Methods for treating conditions associated with masp-2 dependent complement activationOMEROS CORP·Filed 2009·Application pending·0 cites
- 4066US2015239985A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2014·Application pending·0 cites
- 4166US2021355236A1Methods for inhibiting fibrosis in a subject in need thereofUNIV LEICESTER·Filed 2021·Application pending·0 cites
- 4266US2019127484A1Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and DisordersOMEROS CORP·Filed 2018·Application pending·0 cites
- 4366US2019292272A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2018·Application pending·0 cites
- 4465US2020369782A1Monoclonal Antibodies, Compositions and Methods for Detecting Mucin-like Protein (MLP) as a Biomarker for Ovarian and Pancreatic CancerUNIV LEICESTER·Filed 2020·Application pending·0 cites
- 4564US10202465B2Methods for treating conditions associated with MASP-2 dependent complement activationOMEROS CORP·Filed 2016·Granted Feb 12, 2019·0 cites·11 claims
- 4664US2018291111A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2018·Application pending·0 cites
- 4763US2013344073A1Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and DisordersUNIV LEICESTER·Filed 2013·Application pending·0 cites
- 4863US2015166675A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2014·Application pending·0 cites
- 4962US2013266559A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationUNIV LEICESTER·Filed 2013·Application pending·0 cites
- 5062US2023391889A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationUNIV LEICESTER·Filed 2023·Application pending·0 cites
Showing the top 50 of 75 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Hans-Wilhelm Schwaeble files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →